FDA Warns on Direct-to-Clinic Promotion of Illicit Cancer Drugs

Drug Industry Daily
A A
FDA is advising healthcare providers to be on the lookout for fake cancer drugs, after the agency learned of U.S. clinics receiving promotions for unapproved injectables from third-party sources.

To View This Article:

Login

Subscribe To Drug Industry Daily